ReviewCancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Keywords: Tumour immunity; Cancer immunotherapy; Immune checkpoint blockade; Cytotoxic T lymphocyte antigen-4 (CTLA-4); Programmed death-1 (PD-1); Programmed death ligand-1 (PD-L1);